These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 1638024)

  • 41. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis.
    Laï JL; Zandecki M; Mary JY; Bernardi F; Izydorczyk V; Flactif M; Morel P; Jouet JP; Bauters F; Facon T
    Blood; 1995 May; 85(9):2490-7. PubMed ID: 7537117
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.
    Papadaki H; Kyriakou D; Foudoulakis A; Markidou F; Alexandrakis M; Eliopoulos GD
    Acta Haematol; 1997; 97(4):191-5. PubMed ID: 9158660
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum beta-2-microglobulin in multiple myeloma: relation to presenting features and clinical status.
    Bataille R; Magub M; Grenier J; Donnadio D; Sany J
    Eur J Cancer Clin Oncol; 1982 Jan; 18(1):59-66. PubMed ID: 6177535
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience.
    Jacobson JL; Hussein MA; Barlogie B; Durie BG; Crowley JJ;
    Br J Haematol; 2003 Aug; 122(3):441-50. PubMed ID: 12877671
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Beta 2 microglobulin in multiple myeloma.
    Alexanian R; Barlogie B; Fritsche H
    Am J Hematol; 1985 Dec; 20(4):345-51. PubMed ID: 3907332
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increased serum neopterin concentration as indicator of disease severity and poor survival in multiple myeloma.
    Boccadoro M; Battaglio S; Omedè P; Palumbo AP; Fusaro A; Frieri R; Gallone G; Polloni R; Mosso R; De Filippi PG
    Eur J Haematol; 1991 Oct; 47(4):305-9. PubMed ID: 1954991
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
    Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
    Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical significance of correction of serum beta 2-microglobulin levels for serum creatinine in multiple myeloma.
    Scudla V; Vavrdová V; Budíková M; Indrák K
    Acta Univ Palacki Olomuc Fac Med; 1991; 131():257-64. PubMed ID: 1840347
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy.
    Facon T; Avet-Loiseau H; Guillerm G; Moreau P; Geneviève F; Zandecki M; Laï JL; Leleu X; Jouet JP; Bauters F; Harousseau JL; Bataille R; Mary JY;
    Blood; 2001 Mar; 97(6):1566-71. PubMed ID: 11238092
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Values of Detecting the Levels of β2-MG, TNF-α, CRP, IL-6 in the Patients with Multiple Myeloma].
    Duan LJ; Li C; Yang RY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1362-5. PubMed ID: 26524038
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.
    Mihou D; Katodritou E; Zervas K
    Hematology; 2007 Dec; 12(6):527-31. PubMed ID: 17852450
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnostic value of serum IL-6 level in monoclonal gammopathies.
    DuVillard L; Guiguet M; Casasnovas RO; Caillot D; Monnier-Zeller V; Bernard A; Guy H; Solary E
    Br J Haematol; 1995 Feb; 89(2):243-9. PubMed ID: 7873373
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Prognostic value of serum beta2-microglobulin in multiple myeloma].
    Bettini R; Redaelli S; Maino C; Bertuol S; Costantini C; Lazzarini A; Brivio L; Gorini M
    Recenti Prog Med; 2005 Feb; 96(2):81-6. PubMed ID: 15844767
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia.
    Kantarjian HM; Smith T; Estey E; Polyzos A; O'Brien S; Pierce S; Beran M; Feldman E; Keating MJ
    Am J Med; 1992 Dec; 93(6):599-604. PubMed ID: 1466355
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma.
    Mathiot C; Teillaud JL; Elmalek M; Mosseri V; Euller-Ziegler L; Daragon A; Grosbois B; Michaux JL; Facon T; Bernard JF
    J Clin Immunol; 1993 Jan; 13(1):41-8. PubMed ID: 8445043
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Circulating angiogenic cytokines in multiple myeloma and related disorders.
    Urba ska-Rys H; Wierzbowska A; Robak T
    Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity.
    Alexandrakis MG; Passam FH; Kyriakou DS; Christophoridou AV; Perisinakis K; Hatzivasili A; Foudoulakis A; Castanas E
    Am J Hematol; 2004 Feb; 75(2):101-6. PubMed ID: 14755377
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Role of the assay of serum beta 2 microglobulin in the clinical evaluation of myeloma].
    Bataille R; Grenier J
    Presse Med; 1986 Oct; 15(34):1723-5. PubMed ID: 2947132
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor load in patients with multiple myeloma: β₂-microglobulin levels versus low-dose whole-body CT.
    Pfahler V; D'Anastasi M; Dürr HR; Schinner R; Ricke J; Baur-Melnyk A
    Eur J Haematol; 2020 May; 104(5):383-389. PubMed ID: 31762076
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Prognostic factors in multiple myeloma. Review of the literature].
    Bauduer F; Troussard X; Delmer A
    Bull Cancer; 1993 Dec; 80(12):1035-42. PubMed ID: 8081040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.